Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jeffrey John Popma, M.D.

Co-Author

This page shows the publications co-authored by Jeffrey Popma and Michael Jaff.
Connection Strength

0.987
  1. IN.PACT SFA Clinical Study Using the IN.PACT Admiral Drug-Coated Balloon in a Chinese Patient Population. J Endovasc Ther. 2019 08; 26(4):471-478.
    View in: PubMed
    Score: 0.205
  2. Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I): 2-Year Clinical and Imaging Results. JACC Cardiovasc Interv. 2016 06 13; 9(11):1178-87.
    View in: PubMed
    Score: 0.166
  3. Significant reduction in systolic blood pressure following renal artery stenting in patients with uncontrolled hypertension: results from the HERCULES trial. Catheter Cardiovasc Interv. 2012 Sep 01; 80(3):343-50.
    View in: PubMed
    Score: 0.127
  4. Three-Year Efficacy and Safety of the Misago Peripheral Stent for Superficial Femoral Artery Disease: Final Results from the OSPREY Trial. J Vasc Interv Radiol. 2020 Jun; 31(6):978-985.
    View in: PubMed
    Score: 0.055
  5. iCAST Balloon-Expandable Covered Stent for Iliac Artery Lesions: 3-Year Results from the iCARUS Multicenter Study. J Vasc Interv Radiol. 2019 Jun; 30(6):822-829.e4.
    View in: PubMed
    Score: 0.051
  6. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet. 2018 10 27; 392(10157):1541-1551.
    View in: PubMed
    Score: 0.049
  7. A Quantitative Angiographic Comparison of Restenotic Tissue Following Placement of Drug-Eluting Stents and Bare Metal Stents in Symptomatic Patients With Femoropopliteal Disease. J Endovasc Ther. 2017 Aug; 24(4):499-503.
    View in: PubMed
    Score: 0.044
  8. SUPERB final 3-year outcomes using interwoven nitinol biomimetic supera stent. Catheter Cardiovasc Interv. 2017 Jun 01; 89(7):1259-1267.
    View in: PubMed
    Score: 0.044
  9. One-year outcomes of the U.S. and Japanese regulatory trial of the Misago stent for treatment of superficial femoral artery disease (OSPREY study). J Vasc Surg. 2016 Feb; 63(2):370-6.e1.
    View in: PubMed
    Score: 0.040
  10. Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries: Twelve-Month Results of the SUPERB Trial. Circ Cardiovasc Interv. 2015 May; 8(5).
    View in: PubMed
    Score: 0.039
  11. Proper patient selection yields significant and sustained reduction in systolic blood pressure following renal artery stenting in patients with uncontrolled hypertension: long-term results from the HERCULES trial. J Clin Hypertens (Greenwich). 2014 Jul; 16(7):497-503.
    View in: PubMed
    Score: 0.036
  12. Nitinol stent implantation in the superficial femoral artery and proximal popliteal artery: twelve-month results from the complete SE multicenter trial. J Endovasc Ther. 2014 Apr; 21(2):202-12.
    View in: PubMed
    Score: 0.036
  13. Zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors. J Am Coll Cardiol. 2012 Dec 25; 60(25):2618-27.
    View in: PubMed
    Score: 0.033
  14. Excimer laser recanalization of femoropopliteal lesions and 1-year patency: results of the CELLO registry. J Endovasc Ther. 2009 Dec; 16(6):665-75.
    View in: PubMed
    Score: 0.026
  15. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004 Oct 07; 351(15):1493-501.
    View in: PubMed
    Score: 0.019
  16. The Nitinol SMART stent vs Wallstent for suboptimal iliac artery angioplasty: CRISP-US trial results. J Vasc Interv Radiol. 2004 Sep; 15(9):911-8.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.